These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 31637999)

  • 1. Improving drug discovery using image-based multiparametric analysis of the epigenetic landscape.
    Farhy C; Hariharan S; Ylanko J; Orozco L; Zeng FY; Pass I; Ugarte F; Forsberg EC; Huang CT; Andrews DW; Terskikh AV
    Elife; 2019 Oct; 8():. PubMed ID: 31637999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using the molecular classification of glioblastoma to inform personalized treatment.
    Olar A; Aldape KD
    J Pathol; 2014 Jan; 232(2):165-77. PubMed ID: 24114756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accelerating glioblastoma drug discovery: Convergence of patient-derived models, genome editing and phenotypic screening.
    O'Duibhir E; Carragher NO; Pollard SM
    Mol Cell Neurosci; 2017 Apr; 80():198-207. PubMed ID: 27825983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell line with endogenous EGFRvIII expression is a suitable model for research and drug development purposes.
    Stec WJ; Rosiak K; Siejka P; Peciak J; Popeda M; Banaszczyk M; Pawlowska R; Treda C; Hulas-Bigoszewska K; Piaskowski S; Stoczynska-Fidelus E; Rieske P
    Oncotarget; 2016 May; 7(22):31907-25. PubMed ID: 27004406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
    Daher A; de Groot J
    Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An update on the epigenetics of glioblastomas.
    Ferreira WA; Pinheiro Ddo R; Costa Junior CA; Rodrigues-Antunes S; Araújo MD; Leão Barros MB; Teixeira AC; Faro TA; Burbano RR; Oliveira EH; Harada ML; Borges Bdo N
    Epigenomics; 2016 Sep; 8(9):1289-305. PubMed ID: 27585647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Epigenetic regulation in glioblastomas].
    Quillien V
    Ann Pathol; 2009 Nov; 29 Spec No 1():S34-6. PubMed ID: 19887247
    [No Abstract]   [Full Text] [Related]  

  • 8. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
    Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
    Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
    Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M
    Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic modulation of metabolism in glioblastoma.
    Dong Z; Cui H
    Semin Cancer Biol; 2019 Aug; 57():45-51. PubMed ID: 30205139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glioblastoma targeted therapy: updated approaches from recent biological insights.
    Touat M; Idbaih A; Sanson M; Ligon KL
    Ann Oncol; 2017 Jul; 28(7):1457-1472. PubMed ID: 28863449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of histone deacetylase inhibitory prodrugs on epigenetic changes and DNA damage response in tumor and heart of glioblastoma xenograft.
    Tarasenko N; Nudelman A; Rozic G; Cutts SM; Rephaeli A
    Invest New Drugs; 2017 Aug; 35(4):412-426. PubMed ID: 28315153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma.
    Skaga E; Kulesskiy E; Fayzullin A; Sandberg CJ; Potdar S; Kyttälä A; Langmoen IA; Laakso A; Gaál-Paavola E; Perola M; Wennerberg K; Vik-Mo EO
    BMC Cancer; 2019 Jun; 19(1):628. PubMed ID: 31238897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspectives on the discovery of small-molecule modulators for epigenetic processes.
    Lu Q; Quinn AM; Patel MP; Semus SF; Graves AP; Bandyopadhyay D; Pope AJ; Thrall SH
    J Biomol Screen; 2012 Jun; 17(5):555-71. PubMed ID: 22392809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MRI study identifies three subtypes of glioblastoma.
    Brower V
    Lancet Oncol; 2015 Oct; 16(13):e484. PubMed ID: 26365415
    [No Abstract]   [Full Text] [Related]  

  • 16. Mitochondria and nucleus cross-talk: Signaling in metabolism, apoptosis, and differentiation, and function in cancer.
    Shteinfer-Kuzmine A; Verma A; Arif T; Aizenberg O; Paul A; Shoshan-Barmaz V
    IUBMB Life; 2021 Mar; 73(3):492-510. PubMed ID: 33179373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences among brain tumor stem cell types and fetal neural stem cells in focal regions of histone modifications and DNA methylation, broad regions of modifications, and bivalent promoters.
    Yoo S; Bieda MC
    BMC Genomics; 2014 Aug; 15(1):724. PubMed ID: 25163646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surfaceome Proteomic of Glioblastoma Revealed Potential Targets for Immunotherapy.
    Rose M; Cardon T; Aboulouard S; Hajjaji N; Kobeissy F; Duhamel M; Fournier I; Salzet M
    Front Immunol; 2021; 12():746168. PubMed ID: 34646273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current trends in epigenetic drug discovery.
    Stolfa DA; Einsle O; Sippl W; Jung M
    Future Med Chem; 2012 Oct; 4(16):2029-37. PubMed ID: 23157236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma.
    Qazi MA; Vora P; Venugopal C; Sidhu SS; Moffat J; Swanton C; Singh SK
    Ann Oncol; 2017 Jul; 28(7):1448-1456. PubMed ID: 28407030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.